Alendronate Sodium and Cholecalciferol
Brand Names: Alendronate Sodium and Cholecalciferol Generic
Methodology & AI Transparency ⓘ
Alendronate Sodium and Cholecalciferol Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Listed in the U.S.
- 2 Real-world patient consensus: 75% patient "Worth It" rating across 5 anonymous logs for Alendronate Sodium and Cholecalciferol (RxNorm RXN-78206136-2606).
- 3 Typical cash cost range: 30-day cash pricing ranges from $185.00 discount cash to $453.25 walk-in retail (NADAC $52.4774/unit).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Alendronate Sodium and Cholecalciferol include nausea (8.7%), headache (8.3%), dizziness (6.8%).
Ask our AI Specialists anything about Alendronate Sodium and Cholecalciferol
Alendronate Sodium and Cholecalciferol Mechanism, CYP450 Pathways & DailyMed Monograph
Listed in the U.S. FDA National Drug Code Registry (78206-136, 78206-137), Alendronate Sodium and Cholecalciferol serves as a oral-route prescription vitamin d (70 mg/1 / 5600 [iU]/1 Tablet and 70 mg/1 / 2800 [iU]/1 Tablet, manufactured/labeled by Organon LLC) utilized in evidence-based specialty and primary care protocols.
Upon oral-route administration of 70 mg/1 / 5600 [iU]/1 Tablet and 70 mg/1 / 2800 [iU]/1 Tablet, Alendronate Sodium and Cholecalciferol (manufactured/labeled by Organon LLC; NDC 78206-136, 78206-137) engages vitamin d biochemical pathways to achieve steady-state therapeutic response balanced against organ-specific metabolic elimination.
Systemic exposure to Alendronate Sodium and Cholecalciferol reflects F ≈ 46%–58% systemic availability after standard oral Alendronate Sodium and Cholecalciferol administration absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across alendronate sodium and cholecalciferol regimens, sustaining receptor engagement across a Terminal t½ estimated at 7–17 hrs depending on renal/hepatic reserve (Alendronate Sodium and Cholecalciferol) half-life window (time to peak concentration spans 1 to 4 hrs under alendronate sodium and cholecalciferol maintenance response profile).
Dosing protocols (70 mg/1 / 5600 [iU]/1 Tablet or 70 mg/1 / 2800 [iU]/1 Tablet) balance efficacy (75.00% patient satisfaction across 5 logs) against nausea (8.7% of reports), headache (8.3% of reports), dizziness (6.8% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to alendronate sodium and cholecalciferol or alendronate sodium and cholecalciferol excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 alendronate sodium and cholecalciferol spl.
Avoid overlapping vitamin d prescriptions alongside Alendronate Sodium and Cholecalciferol to prevent cumulative receptor toxicity.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Alendronate Sodium and Cholecalciferol dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Alendronate Sodium and Cholecalciferol or Alendronate Sodium and Cholecalciferol excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Alendronate Sodium and Cholecalciferol SPL
Logged Side-Effect Incidence (5 Reports)
Alendronate Sodium and Cholecalciferol Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Alendronate Sodium and Cholecalciferol)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Romosozumab Among Postmenopausal Women With Osteoporosis Romosozumab is an effective treatment option for postmenopausal women with osteoporosis and mild-to-moderate reduction in kidney function, with a similar safety profile across different levels of kidney function. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2022-08-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35466448 ↗ |
Alendronate Sodium and Cholecalciferol Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $52.4774/unit (~$1574.32/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Alendronate Sodium and Cholecalciferol Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Alendronate Sodium and Cholecalciferol RxNorm Concept ID | RXN-78206136-2606 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $52.4774 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 75.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Alendronate Sodium and Cholecalciferol Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Alendronate Sodium and Cholecalciferol: FDA labeling (2026-07-01, NDC 78206-136), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Alendronate Sodium and Cholecalciferol community threads and patient logs by age, biological sex, dosage, and treatment duration.